The role of corticosteroids in the treatment of pain in cancer patients

Wojciech Leppert, Tomasz Buss, Wojciech Leppert, Tomasz Buss

Abstract

Pain is one of the most frequent and most distressing symptoms in the course of cancer. The management of pain in cancer patients is based on the concept of the World Health Organization (WHO) analgesic ladder and was recently updated with the EAPC (European Association for Palliative Care) recommendations. Cancer pain may be relieved effectively with opioids administered alone or in combination with adjuvant analgesics. Corticosteroids are commonly used adjuvant analgesics and play an important role in neuropathic and bone pain treatment. However, in spite of the common use of corticosteroids, there is limited scientific evidence demonstrating their efficacy in cancer patients with pain. The use of corticosteroids in spinal cord compression, superior vena cava obstruction, raised intracranial pressure, and bowel obstruction is better established than in other nonspecific indications. This review aims to present the role of steroids in pain and management of other symptoms in cancer patients according to the available data, and discusses practical aspects of steroid use.

References

    1. World Health Organisation . Cancer pain relief and palliative care. Geneva: World Health Organisation; 1996.
    1. Caraceni A. The EPCRC project to revise the European Association for Palliative Care (EAPC) guidelines on the use of opioids for cancer pain. Palliat Med. 2011;25:389–390. doi: 10.1177/0269216310395871.
    1. •• Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N et al., for the European Palliative Care Research Collaborative (EPCRC) on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-e68. This paper presents current EAPC recommendations on the use of opioids in the treatment of pain in cancer patients.
    1. Shvartzman P, Friger M, Shani A, Barak F, Yoram C, Singer Y. Pain control in ambulatory cancer patients—can we do better? J Pain Symptom Manag. 2003;26:716–722. doi: 10.1016/S0885-3924(03)00220-3.
    1. Leppert W. Progress in pharmacological pain treatment with opioid analgesics. Wspolcz Onkol-Contemp Oncol. 2009;13:66–73.
    1. Eidelman A, White T, Swarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Nat Compr Cancer Net. 2007;5:753–760.
    1. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9:571–591. doi: 10.1634/theoncologist.9-5-571.
    1. Leppert W. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Head Rep. 2011;15:271–279. doi: 10.1007/s11916-011-0201-7.
    1. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44:1105–1115. doi: 10.1016/j.ejca.2008.02.028.
    1. Aron DC, Findling JW, Tyrell B. Glucocorticoids and adrenal androgens. In: Gardner DG, Shoback D, editors. Greenspan’s Basic and clinical endocrinology. 8th ed. New York: McGraw Hill; 2007. pp. 346–396.
    1. Stewart PM. The adrenal cortex. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Textbook of endocrinology. Philadelphia: Saunders; 2002. pp. 491–507.
    1. Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders—a systematic review. Endocrinol Metabol Clin N Am. 2002;31(3):751. doi: 10.1016/S0889-8529(02)00008-7.
    1. Livanou T, Ferriman D, James VHT. Recovery of hypotalamo-pituitary-adrenal function after corticosteroid therapy. Lancet. 1967;2(7521):856. doi: 10.1016/S0140-6736(67)92592-5.
    1. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manag. 1994;9:442–445. doi: 10.1016/0885-3924(94)90200-3.
    1. Mensah-Nyagan AG, Meyer L, Schaeffer V, Kibaly C, Patte-Mensah C. Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology. 2009;34(Suppl 1):S169–S177. doi: 10.1016/j.psyneuen.2009.06.004.
    1. Yamada K, Ushio Y, Hayakawa T, Arita N, Yamada N, Mogami H. Effects of methylprednisolone on peritumoral brain oedema—a quantitive autoradiographic study. J Neurosurg. 1983;59:612–619. doi: 10.3171/jns.1983.59.4.0612.
    1. Posner JB, Howieson J, Cvitkovic E. Disappearing spinal-cord compression—oncolytic effect of glucocorticoids (and other chemiotherapeutic agents) on epidural metastases. Ann Neurol. 1977;2:409–413. doi: 10.1002/ana.410020511.
    1. Mensah-Nyagan AG, Kibaly C, Schaeffer V, Venard C, Meyer L, Patte-Mensah C. Endogenous steroid production in the spinal cord and potential involvement in neuropathic pain modulation. J Steroid Biochem Molecul Biol. 2008;109:286–293. doi: 10.1016/j.jsbmb.2008.03.002.
    1. Aloisi AM. Gonadal hormones and sex differences in pain reactivity. Clin J Pain. 2003;19:168–174. doi: 10.1097/00002508-200305000-00004.
    1. Aloisi AM, Bonifazi M. Sex hormones, central nervous system and pain. Hormon Behav. 2006;50:1–7. doi: 10.1016/j.yhbeh.2005.12.002.
    1. Liu NJ, Gintzler AR. Prolonged ovarian sex steroid treatment of male rats produces antinociception: identification of sex-based divergent analgesic mechanisms. Pain. 2000;85:273–281. doi: 10.1016/S0304-3959(99)00278-X.
    1. Lundström SH, Furst CJ. The use of corticosteroids in Swedish palliative care. Acta Oncol. 2006;45:430–437. doi: 10.1080/02841860500401167.
    1. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000;18:1780–1799.
    1. Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med. 2001;15:3–8. doi: 10.1191/026921601673324846.
    1. Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. J Pain Symptom Manag. 2002;24:328–334. doi: 10.1016/S0885-3924(02)00487-6.
    1. Exton L, Walsh D, Caraceni AT, Fainsinger R, Foley K, Glare P, et al. Palliative medicine. Philadelphia: Elsevier; 2009. Corticosteroids; pp. 797–801.
    1. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease—role of nonsteroidal antiinflammatory drugs. Ann Intern Med. 1991;114:735–40.
    1. Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RKS, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16:1041–1048. doi: 10.1007/s00520-007-0395-8.
    1. Hanks GW, Trueman T, Twycross RG. Corticosteroids in terminal cancer—a prospective analysis of current practice. Postgrad Med J. 1983;59:702–706. doi: 10.1136/pgmj.59.697.702.
    1. Kang JH, Hiu D, Kim MJ, Kim HG, Kang MH, Lee GW, et al. Corticosteroid rotation to alleviate dexamethasone-induced hiccup: a case series at a single institution. J Pain Symptom Manag. 2012;43:625–630. doi: 10.1016/j.jpainsymman.2011.04.011.
    1. Dickman A, Schneider J, Varga J. The Syringe driver: continuous subcutaneous infusions in palliative care. Oxford: Oxford University Press; 2005.
    1. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med. 2004;18:100–107. doi: 10.1191/0269216304pm852oa.
    1. Yennurajalingam S, Urbauer DL, Casper KLB, Reyes-Gibby CC, Chacko R, Poulter V. Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J Pain Symptom Manag. 2011;41:49–56. doi: 10.1016/j.jpainsymman.2010.03.017.
    1. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednizolone in terminal cancer patients—a prospective, randomized double-blind study. Cancer Treat Rep. 1985;69:751–754.
    1. Dellacuna GR, Pellegrini A, Piazzi M. Effect of methylprednizolone sodium succinate on quality of life in preterminal cancer patients—a placebo controlled, multicenter study. Eur J Cancer Clin Oncol. 1989;25:1817–1821. doi: 10.1016/0277-5379(89)90353-2.
    1. Popiela T, Lucchi R, Giongo F. Methylpredinsolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol. 1989;25:1823–1829. doi: 10.1016/0277-5379(89)90354-4.
    1. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone—evaluation of psin and quality of life as prgmatic indexes of response. J Clin Oncol. 1989;7:590–597.
    1. Greenberg HS, Kim JH, Posner JB. Epidural spinal-cord compresion from metastatic tumor—results with a new treatment protocol. Ann Neurol. 1980;8:361–366. doi: 10.1002/ana.410080404.
    1. Kozin F, Ryan LM, Carerra GF, Soin JS, Wortmann RL. The reflex sympathetic dystrophy syndrome (RSDS) III. Scintigraphic studies, further evidence for therapeutic efficacy of systemic corticosteroids and proposed diagnostic criteria. Am J Med. 1981;70:23–30. doi: 10.1016/0002-9343(81)90407-1.
    1. Arkel YS, Lakelewin D, Savopoulos AA, Berman E. Bone-lesions in hairy cell leukemia—a case report and response of bone pains to steroids. Cancer. 1984;53:2401–2403. doi: 10.1002/1097-0142(19840601)53:11<2401::AID-CNCR2820531106>;2-R.
    1. Vyvey M. Steroids as pain relief adjuvants. Can Fam Phys. 2010;56:1295–1297.
    1. Moertel CG, Schutt AJ, Reitemei RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974;33:1607–1609. doi: 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>;2-V.
    1. Vecht CJ, Haaxmareiche H, Vanputten WLJ, Devisser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal-cord compression. Neurology. 1989;39:1255–1257. doi: 10.1212/WNL.39.9.1255.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다